India, Sept. 4 -- ENDRA Life Sciences Inc. (NDRA), a medical technology company developing thermoacoustic biomarker imaging for steatotic liver disease, recently reported second-quarter 2026 financial results and provided an update on its proposed merger with Noble Africa.
The company is developing Thermo Acoustic Enhanced UltraSound (TAEUS), a technology designed to assess liver fat content and monitor tissue ablation during minimally invasive procedures.
Q2 Financial Readout:
For the second quarter of 2026, ENDRA reported net income of approximately $160,000, compared with a net loss of approximately $1.2 million in the same period of 2025.
Total operating expenses increased to approximately $1.5 million from $1.3 million a year earli...